DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c33bx7/lampalizumab) has announced the addition of the "Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.
Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway.
- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lampalizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lampalizumab for the top country from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Macular Degeneration Overview
3.2 Macular Edema Overview
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Macular Edema Diagnosis
4.1.2 Macular Degeneration Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
5 Competitive Assessment
6 Unmet Need and Opportunity
6.2 Treatment for Dry AMD
6.3 Longer-Acting Anti-VEGF Drug Therapy
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD
6.5 Less Invasive Drug Formulations
6.6 Awareness and Earlier Patient Diagnosis
6.7 Home Monitoring of AMD Progression
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
For more information visit http://www.researchandmarkets.com/research/c33bx7/lampalizumab